Zobrazeno 1 - 10
of 1 642
pro vyhledávání: ''
Autor:
Atsushi Naganuma, Takaaki Tanaka, Atsushi Hiraoka, Satoshi Yasuda, Kazuya Kariyama, Noritomo Shimada, Shinichiro Nakamura, Satoru Kakizaki, Michitaka Imai, Koichi Takaguchi, Takuya Nagano, Toshifumi Tada, Akemi Tsutsui, Takashi Kumada, Takeshi Hatanaka, Kazuhiro Nouso, Toru Ishikawa, Kunihiko Tsuji, Hidenori Toyoda, Hiroshi Shibata, Ei Itobayashi
Publikováno v:
Oncology
Background/Aim: With the development of systemic treatment methods for unresectable hepatocellular carcinoma (uHCC), the concept of unsuitable for transcatheter arterial chemoembolization (TACE) has become important. This study aimed to establish a s
Autor:
Ines Beilmann-Lehtonen, Ulf-Håkan Stenman, Caj Haglund, Tuomas Kaprio, Kajsa Björkman, Camilla Böckelman
Publikováno v:
Oncology. 100:22-30
Objectives: Colorectal cancer is the third most common cancer worldwide, with an obvious need for more accurate prognostics. Previous studies identified C-reactive protein (CRP) as a prognostic serum biomarker for colorectal cancer, whereas the bioma
Autor:
Mariko Kobayashi, Satoshi Saitoh, Nozomu Muraishi, Masahiro Kobayashi, Fumitaka Suzuki, Kenji Ikeda, Norio Akuta, Yasuji Arase, Shunichiro Fujiyama, Hiromitsu Kumada, Tetsuya Hosaka, Hitomi Sezaki, Yusuke Kawamura, Yoshiyuki Suzuki
Publikováno v:
Oncology
Introduction: It is unclear whether the relationships between changes in fibrosis and circulating microRNA-122 (miR-122) dynamics might influence the prognosis of nonalcoholic fatty liver disease (NAFLD). Methods: This study investigates the impact o
Autor:
Jan-Peter Roth, Francesco Vitali, Dagmar Busse, W Schreiner, Susanne Merkel, Robert Stoehr, Arndt Hartmann, Markus Eckstein, Axel Wein, Stephan Kersting, Michael Uder, Peter Anhut, Robert Grützmann, Jürgen Siebler, Nicola Ostermeier, Markus F. Neurath, Kerstin Wolff, Clemens Neufert
Publikováno v:
Oncology. 100:1-11
Objective: The study aimed to prospectively evaluate a new molecular biomarker panel (KRAS, NRAS, BRAF, PIK3CA, and ERBB2) for palliative first-line treatment of colorectal cancer (CRC), including a multidisciplinary treatment approach. The rate of s
Autor:
Mónica Chapa-Ibargüengoitia, Yuly A Remolina-Bonilla, Nayeli Martínez-Ibarra, Gabriela Hernández-Molina, Francisco J Castro-Alonso, Maria T Bourlon, Armando Gamboa-Domínguez, Emilio Conde-Flores
Publikováno v:
ONCOLOGY. :486-490
This clinical quandary details a Mexican man, aged 77 years, who presented to the oncology clinic with a sternal mass. Based on the results, the patient fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism classifica
Autor:
Gi-Ming Wang, Kristen Waite, Nakayama John, Jill S. Barnholtz-Sloan, Nirav Patil, Gino Cioffi, Ravi Kumar Kyasaram, John Shanahan, Paolo Caimi
Publikováno v:
ONCOLOGY. :462-470
Objectives: COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic. Methods: This case-controlled trial evaluated more than 345,000 oncologic clinic, lab
Autor:
Mehmet Sitki Copur, Thomas Zusag, Nicholas Lintel, John Allen, Wendel Whitney, Paul Rodriguez, Scott Bell
Publikováno v:
ONCOLOGY. :128-133
Spinal cord compression is a potentially devastating consequence of cancer. Early recognition of the signs and symptoms permit diagnosis prior to the development of irreversible neurological damage. This complication occurs in 5% to 10% of patients w
Publikováno v:
ONCOLOGY. :111-118
Background With fewer than 7% of patients with small cell lung cancer (SCLC) surviving 5 years after diagnosis, the receipt of recommended treatment is of utmost importance for patient survival. Nevertheless, treatment refusal by patients with SCLC h
Autor:
Yukio Miki, Kohei Kotani, Kanako Yoshida, Kenjiro Kimura, Naoshi Odagiri, Sawako Uchida-Kobayashi, Akihiro Tamori, Hiroko Ikenaga, Shoji Kubo, Atsushi Hagihara, Ken Kageyama, Masaru Enomoto, Norifumi Kawada, Akira Yamamoto, Hideki Fujii
Publikováno v:
Oncology. 99(3):186-191
Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-relate
Autor:
Alla Berlin, Leora Brazg Ferro, Ester Osher, Orit Gutfeld, Inbal Golomb, Inna Ospovat, Viacheslav Soyfer, Ido Wolf, Shira Peleg Hasson
Publikováno v:
Oncology. 99:373-379
Introduction: Extrapulmonary small-cell cancer (EPSCC) is a relatively rare malignancy. The management of EPSCC is usually extrapolated from small-cell lung cancer (SCLC). In spite of the morphological similarity of the 2 malignancies, there are many